PHILADELPHIA (AFX) - GlaxoSmithKline said interim results from a Phase 2 clinical trial in patients treated with GSK's investigational MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) in non-small cell lung cancer resulted in a one-third reduction in relative risk of cancer recurrence following surgery, compared to placebo.
MAGE-A3 ASCI is an investigational drug and it is not approved for use in any indication in any country at this time.
Formerly known as pharmaccines or therapeutic cancer vaccines, GSK's ASCIs aim at stimulating the patient's own immune response to attack cancer cells in a highly specific manner.
The results from this interim analysis were presented at the American Society of Clinical Oncology annual meeting in Atlanta. newsdesk@afxnews.com vs/vs COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited